Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 2
1994 1
1995 3
1996 14
1997 20
1998 21
1999 25
2000 33
2001 22
2002 33
2003 42
2004 42
2005 41
2006 52
2007 42
2008 42
2009 32
2010 23
2011 38
2012 27
2013 34
2014 24
2015 14
2016 12
2017 22
2018 14
2019 20
2020 26
2021 18
2022 19
2023 21
2024 14
2025 19
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

746 results

Results by year

Filters applied: . Clear all
Page 1
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. Saag KG, et al. N Engl J Med. 2017 Oct 12;377(15):1417-1427. doi: 10.1056/NEJMoa1708322. Epub 2017 Sep 11. N Engl J Med. 2017. PMID: 28892457 Free article. Clinical Trial.
BACKGROUND: Romosozumab is a monoclonal antibody that binds to and inhibits sclerostin, increases bone formation, and decreases bone resorption. METHODS: We enrolled 4093 postmenopausal women with osteoporosis and a fragility fracture and randomly assi …
BACKGROUND: Romosozumab is a monoclonal antibody that binds to and inhibits sclerostin, increases bone formation, and decreases bo …
Comparative effectiveness of denosumab vs alendronate among postmenopausal women with osteoporosis.
Curtis JR, Arora T, Liu Y, Lin TC, Spangler L, Brunetti VC, Stad RK, McDermott M, Bradbury BD, Kim M. Curtis JR, et al. J Bone Miner Res. 2024 Aug 5;39(7):826-834. doi: 10.1093/jbmr/zjae079. J Bone Miner Res. 2024. PMID: 38753892 Free PMC article.
Although clinical trials have shown that denosumab is more effective at increasing bone mineral density compared with alendronate, there is a lack of evidence evaluating the fracture risk between these 2 commonly used osteoporosis therapies. In this study usi …
Although clinical trials have shown that denosumab is more effective at increasing bone mineral density compared with alendronate …
Osteoporosis in elderly: prevention and treatment.
Srivastava M, Deal C. Srivastava M, et al. Clin Geriatr Med. 2002 Aug;18(3):529-55. doi: 10.1016/s0749-0690(02)00022-8. Clin Geriatr Med. 2002. PMID: 12424871 Review.
Osteoporosis is a major clinical problem in older women and men. Almost any bone can fracture as a result of the increased bone fragility of osteoporosis. These fractures are associated with higher health care costs, physical disability, impaired quali …
Osteoporosis is a major clinical problem in older women and men. Almost any bone can fracture as a result of the increased …
Prevention and treatment of postmenopausal osteoporosis.
Tella SH, Gallagher JC. Tella SH, et al. J Steroid Biochem Mol Biol. 2014 Jul;142:155-70. doi: 10.1016/j.jsbmb.2013.09.008. Epub 2013 Oct 29. J Steroid Biochem Mol Biol. 2014. PMID: 24176761 Free PMC article. Review.
In the beginning, that is from the 1960's, when a link between menopause and osteoporosis was first identified; estrogen treatment was the standard for preventing bone loss, however there was no fracture data, even though it was thought to be effective. ...Re …
In the beginning, that is from the 1960's, when a link between menopause and osteoporosis was first identified; estrogen treatment was the s …
Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
Ayers C, Kansagara D, Lazur B, Fu R, Kwon A, Harrod C. Ayers C, et al. Ann Intern Med. 2023 Feb;176(2):182-195. doi: 10.7326/M22-0684. Epub 2023 Jan 3. Ann Intern Med. 2023. PMID: 36592455 Free article.
Raloxifene and bazedoxifene for 36 months or more reduced radiographic vertebral but not clinical fractures (low to moderate CoE). Abaloparatide, teriparatide, and sequential romosozumab, then alendronate, may be more effective than bisphosphonates in reducing clini …
Raloxifene and bazedoxifene for 36 months or more reduced radiographic vertebral but not clinical fractures (low to moderate CoE). Ab …
Time to Benefit of Bisphosphonate Therapy for the Prevention of Fractures Among Postmenopausal Women With Osteoporosis: A Meta-analysis of Randomized Clinical Trials.
Deardorff WJ, Cenzer I, Nguyen B, Lee SJ. Deardorff WJ, et al. JAMA Intern Med. 2022 Jan 1;182(1):33-41. doi: 10.1001/jamainternmed.2021.6745. JAMA Intern Med. 2022. PMID: 34807231 Free PMC article.
STUDY SELECTION: Studies selected were RCTs involving postmenopausal women with a diagnosis of osteoporosis based on existing vertebral fractures or bone mineral density T scores of -2.5 or lower. ...To prevent 1 hip fracture, 200 postmenopau …
STUDY SELECTION: Studies selected were RCTs involving postmenopausal women with a diagnosis of osteoporosis based on existing vertebr …
FABP4 inhibition suppresses bone resorption and protects against postmenopausal osteoporosis in ovariectomized mice.
Xie Q, Du X, Liang J, Shen Y, Ling Y, Huang Z, Ke Z, Li T, Song B, Wu T, Wang Y, Tao H. Xie Q, et al. Nat Commun. 2025 May 13;16(1):4437. doi: 10.1038/s41467-025-59719-w. Nat Commun. 2025. PMID: 40360512 Free PMC article.
Postmenopausal osteoporosis (PMOP) is a condition in women caused by estrogen deficiency, characterized by reduced bone mass and increased fracture risk. ...Oral BMS309403 increases bone mineral density in ovariectomized mice, though less effectively t …
Postmenopausal osteoporosis (PMOP) is a condition in women caused by estrogen deficiency, characterized by reduced bone mass a …
Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis.
Barrionuevo P, Kapoor E, Asi N, Alahdab F, Mohammed K, Benkhadra K, Almasri J, Farah W, Sarigianni M, Muthusamy K, Al Nofal A, Haydour Q, Wang Z, Murad MH. Barrionuevo P, et al. J Clin Endocrinol Metab. 2019 May 1;104(5):1623-1630. doi: 10.1210/jc.2019-00192. J Clin Endocrinol Metab. 2019. PMID: 30907957 Free article.
BACKGROUND: Osteoporosis and osteopenia are associated with increased fracture incidence in postmenopausal women. We aimed to determine the comparative effectiveness of various available pharmacological therapies. ...RESULTS: We included 107 trials (193,987 postm …
BACKGROUND: Osteoporosis and osteopenia are associated with increased fracture incidence in postmenopausal women. We aimed to …
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Black DM, et al. Lancet. 1996 Dec 7;348(9041):1535-41. doi: 10.1016/s0140-6736(96)07088-2. Lancet. 1996. PMID: 8950879 Clinical Trial.
BACKGROUND: Previous studies have shown that alendronate can increase bone mineral density (BMD) and prevent radiographically defined (morphometric) vertebral fractures. The Fracture Intervention Trial aimed to investigate the effect of alend …
BACKGROUND: Previous studies have shown that alendronate can increase bone mineral density (BMD) and prevent radiograph …
Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Wells GA, Hsieh SC, Peterson J, Zheng C, Kelly SE, Shea B, Tugwell P. Wells GA, et al. Cochrane Database Syst Rev. 2025 Jan 27;1(1):CD001155. doi: 10.1002/14651858.CD001155.pub3. Cochrane Database Syst Rev. 2025. PMID: 39868546 Free PMC article.
RATIONALE: Osteoporosis is an abnormal reduction in bone mass and bone deterioration, leading to increased fracture risk. Alendronate belongs to the bisphosphonate class of drugs, which inhibit bone resorption by interfering with the activity of …
RATIONALE: Osteoporosis is an abnormal reduction in bone mass and bone deterioration, leading to increased fracture ris …
746 results